 BrainsWay Ltd. NASDAQ TASE: BWAY BrainsWay today announced interim results from a multicenter randomized controlled double-blind clinical trial assessing the safety and efficacy of the Companys H7-coil deep transcranial magnetic stimulation dTMS System for the treatment of adults with post-traumatic stress disorder PTSD. Results showed that the H7 dTMS, which targets the medial prefrontal cortex mPFC, did not demonstrate sufficient efficacy relative to sham control treatment in PTSD patients. Based on the interim analysis, the Company will not invest additional resources in order to continue this study. 